RNAi Molecule definition

RNAi Molecule means an exogenous double-stranded oligomeric (i.e., RNA or modified variants thereof) molecule incorporating N-acetyl-galactosamine (GalNAc) ligand conjugates capable of binding to the asialoglycoprotein receptor (ASGPR) to enhance targeting to the liver.

RNAi Molecule means a double stranded RNA molecule that induces sequence specific downregulation of target gene expression in a cell, where the double stranded RNA molecule has two separate complementary strands or a single strand having two complementary parts that hybridise.

RNAi Molecule means [***].

Examples of RNAi Molecule in a sentence

• During the Research Collaboration Term, Silence shall have the right to make any publications, presentations, or public disclosures related to an RNAi Molecule or a Licensed Compound subject to AZ’s prior review and approval.

• Xxxxxxx and Arrowhead also agreed to a research collaboration to develop RNAi therapeutics directed against additional targets using Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform.

• Prior to AZ’s exercise of an Option in respect of a particular Selected Target, AZ may not make any publications, presentations, or public disclosures solely related to an RNAi Molecule, Licensed Compound or Licensed Product without Silence’s prior written approval.

• PlatformIn 2020, Arrowhead continued to develop and deploy our Targeted RNAi Molecule platform (“TRiM™) to identify and develop new therapeutics, including ARO-Lung2 and ARO-COV.

• Arrowhead has focused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology.

• We are happy to announce today that Arrowhead and Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson and Johnson, have signed a license agreement whereby Janssen gets an exclusive worldwide license to Arrowhead’s ARO-HBV program and also a collaboration agreement for up to three new candidates utilizing our proprietary Targeted RNAi Molecule, or TRiMTM, platform against targets to be selected by Janssen.

• PlatformIn fiscal 2021, Arrowhead continued to develop and deploy our Targeted RNAi Molecule platform (“TRiM™) to identify and develop new therapeutics,including ARO-DUX4.

• PlatformIn 2019, we continued to develop and deploy our Targeted RNAi Molecule platform, or TRiM™, to identify and develop new therapeutics, including ARO-HIF2, ARO-HSD, and ARO-ENaC .

• A Party seeking publication shall provide the other Party the opportunity to review and comment on any proposed publication (or where a copy of such publication or presentation is not available at such time, a draft or outline of such publication or description of such presentation) that relates to an RNAi Molecule directed to the Collaboration Target or any Compound or Product, at least [***] days prior to its intended submission for publication.

• PlatformIn 2020, Arrowhead continued to develop and deploy our Targeted RNAi Molecule platform (“TRiM™) to identify and develop new therapeutics, including ARO-Lung2 and ARO-COV.

More Definitions of RNAi Molecule

RNAi Molecule means any exogenous double-stranded oligonucleotide (i.e. RNA or modified variants thereof) molecule inducing RISC-mediated cleavage and degradation of the target RNA (where RISC means RNA-induced silencing complex).

RNAi Molecule means a molecule comprising an exogenous double-stranded oligonucleotide (i.e., RNA or modified variants thereof) comprising a nucleotide sequence designed to inhibit the expression of a gene using the RNA interference mechanism. “Royalties” means (i) any and all royalty payments received by or on behalf of Borrower or its Subsidiaries under any Permitted Product Agreement with respect to a Product, (ii) any and all payments received by Borrower or its Subsidiaries in lieu of such payments described in the foregoing clause (i) under the applicable Permitted Product Agreement, (iii) any and all interest payments received by or on behalf of Borrower or its Subsidiaries under a Permitted Product Agreement assessed on any payments or amounts described in the foregoing clauses (i) and (ii), and (iv) without duplication of any payment actually made under clauses (i), (ii) and (iii), any and all “proceeds” recoverable or recovered with respect to any of the foregoing. “Royalty Monetization Transaction” means any monetization transaction involving the sale, transfer, option or collateralization of (i) any monetary payments (contingent or otherwise) payable to Borrower or its Subsidiaries by a counterparty under a Product Agreement (including any Royalties, Milestones and Profit Share Amounts payable thereunder), or (ii) any Product Revenues, in each case whether in whole or in part, in each case (i) and (ii) including but not limited to sales of royalty streams, royalty bonds and other royalty financings, synthetic royalty and revenue interest transactions (including but not limited to clinical trial funding arrangements), and hybrid monetization transactions. “Royalty Reports” means any royalty reports, net sales reports or other similar reports deliverable by a counterparty pursuant to any Permitted Product Agreement. “RPI Agreement” means that certain Royalty Purchase Agreement by and between Borrower and Royalty Pharma Investments 2019 ICAV, dated as of November 9, 2022. “RPI Milestones” means the “Additional Purchase Price Payments” payable to Borrower pursuant to Section 2.1(b) of the RPI Agreement. “S&P” means Standard & Poor’s Ratings Group, a division of The McGraw Hill Corporation. “Sanctioned Entity” means (a) a country or territory or a government of a country or territory, (b) an agency of the government of a country or territory, (c) an organization directly or indirectly controlled by a country or territory or its government, or (d) a Person residen...